Ruin Moaddel

USPTO Granted Patents = 7 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 37(Granted Patents)

Location History:

Germantown, MD (US) (2010)
Bel Air, MD (US) (2017 - 2023)

Company Filing History:

7 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

2 out of 8

The Cooper Health System

University System of Maryland

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473251 - Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine (2025-11-18),

2. 12325688 - Gingerenone A prodrugs as sensotherapeutics and methods of use (2025-06-10),

3. 11613514 - Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine (2023-03-28),

4. 10919842 - Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine (2021-02-16),

5. 9867830 - Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain (2018-01-16),

6. 9650352 - Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain (2017-05-16),

7. 7749984 - Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors (2010-07-06),

Title: The Innovative Contributions of Ruin Moaddel

Introduction

Ruin Moaddel is a notable inventor based in Bel Air, MD (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of six patents to his name, he has made strides in developing compounds that address various health issues, particularly those associated with senescence and neuroinflammation.

Latest Patents

One of his latest patents is titled "Gingerenone A prodrugs as sensotherapeutics and methods of use." This patent describes Gingerenone A prodrug compounds that possess a specific structure, which can be utilized for inhibiting or eliminating senescence. These compounds may be administered to individuals suffering from senescence-associated diseases, neuroinflammation, pain, or amino acid deficiencies. Another significant patent involves the "Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine." This disclosure outlines a method for synthesizing free base forms of hydroxynorketamine, including the preparation of (R)-norketamine through chiral resolution.

Career Highlights

Ruin Moaddel has had a distinguished career, working with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and The Cooper Health System. His work in these institutions has allowed him to contribute to significant advancements in medical research and pharmaceutical development.

Collaborations

Throughout his career, Ruin has collaborated with notable colleagues, including Carlos A. Zarate and Irving William Wainer. These collaborations have further enriched his research and innovation efforts.

Conclusion

Ruin Moaddel's innovative work and patents reflect his commitment to advancing medical science and improving health outcomes. His contributions are invaluable in the ongoing quest to develop effective treatments for complex health issues.

This text is generated by artificial intelligence and may not be accurate.